Related Experiment Video
Updated: Sep 24, 2025
In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
Can COVID-19 vaccines improve cardiovascular outcomes?
Chia Siang Kow1, Dinesh Sangarran Ramachandram2, Syed Shahzad Hasan3
1School of Pharmacy, International Medical University, Kuala Lumpur, Malaysia.
Insights
Current COVID-19 vaccine trials focus on severe infection and mortality. Further research is needed to explore potential cardiovascular benefits and address public vaccine hesitancy regarding rare cardiac events.
Area of Science:
- Cardiology
- Vaccinology
- Public Health
Background:
- COVID-19 vaccine efficacy trials primarily assess reduction in severe infection and mortality.
- Concerns exist regarding rare cardiovascular complications, such as myocarditis and pericarditis, associated with certain COVID-19 vaccines (e.g., mRNA vaccines like BNT162b2, mRNA-1273).
- Specious social media reports contribute to vaccine hesitancy despite the mild nature and infrequency of reported cardiac events.
Discussion:
- There is a critical need to investigate the efficacy of COVID-19 vaccines in reducing cardiovascular outcomes.
- Understanding potential cardiovascular benefits could enhance public confidence in vaccine acceptance.
- Prospective studies are essential to definitively establish the relationship between COVID-19 vaccination and cardiovascular health.
Key Insights:
- Existing COVID-19 vaccine research prioritizes severe outcomes over cardiovascular health.
- Investigating cardiovascular benefits may mitigate vaccine hesitancy fueled by misinformation.
- The association between COVID-19 vaccines and cardiovascular outcomes requires further rigorous scientific inquiry.
Outlook:
- Future research should focus on prospective studies to evaluate COVID-19 vaccine impact on cardiovascular events.
- Establishing cardiovascular benefits could bolster vaccine confidence and address public concerns.
- This research area is crucial for a comprehensive understanding of vaccine safety and efficacy.
Abstract:
Thus far, the investigations on the efficacy of the COVID-19 vaccines in randomized trials [8,9] have been centered around reducing the risk of severe infection and mortality. We opine investigations on the efficacy of the COVID-19 vaccines to reduce the risk of cardiovascular outcomes should be performed to understand if COVID-19 vaccination has cardiovascular benefits. Such investigations could also develop more confidence toward the acceptance of COVID-19 vaccines by the public, especially when some of the COVID-19 vaccines (particularly the mRNA vaccines such as BNT162b2 and mRNA-1273 vaccines) have been associated with the rare occurrence of cardiovascular complications, including myocarditis and pericarditis [10,11]. While the infrequency and the mild nature of the myocarditis and pericarditis cases after vaccination greatly exceed the small increased risk, specious reports on social media are still fueling the COVID-19 vaccine hesitancy. Therefore, we urge the performance of prospective investigations to establish the relationship between COVID-19 vaccines and cardiovascular outcomes.
More Related Videos
Related Concept Videos
01:26Coronary Artery Disease IV: Preventive Measures
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
01:27Psychoneuroimmunology: Cardiovascular Disease
A key area of focus in PNI is the relationship between stress and coronary...
01:30Coronary Artery Disease III: Clinical Manifestations
01:22Heart Failure Drugs: β-Blockers
01:17Ischemic Heart Disease: Overview
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...